Form 4: Damora Therapeutics Director Receives Stock Options

Damora Therapeutics Director Cameron Turtle was granted 37,313 stock options with an exercise price of $23.05, vesting monthly through March 2029.

Summary

• Cameron Turtle, a Director of Damora Therapeutics, Inc. (DMRA), was granted stock options.
• The grant involves 37,313 derivative securities, representing the right to purchase 37,313 shares of common stock.
• The exercise price for these options is $23.05 per share.
• The transaction date for the option acquisition was March 23, 2026.
• These options will vest in equal monthly installments through March 23, 2029, contingent on Mr. Turtle's continued service to the Issuer.
• The options have an expiration date of March 23, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued alignment of a director's interests with shareholder value through equity compensation, which is a standard and healthy corporate practice.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The vesting schedule over several years encourages sustained commitment and contribution from the director.

Future Outlook

The vesting schedule through March 2029 indicates an expectation of Cameron Turtle's continued service as a Director, aligning his long-term incentives with the company's performance.

Industry Context

StockSavvy.ai notes that granting stock options to directors is a standard practice in corporate governance, serving as a common form of equity compensation to align the interests of directors with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• The grant of stock options to directors is a widely adopted compensation strategy across various industries, including biotechnology and pharmaceuticals, similar to practices at companies like Pfizer or Moderna, where executive and director compensation often includes significant equity components.
• The vesting schedule over several years is typical for long-term incentive plans, comparable to those seen in established tech companies like Apple or Microsoft, designed to retain talent and encourage sustained performance.

Related Party Transactions

• The grant of stock options to Director Cameron Turtle is an insider transaction, a common form of compensation for company leadership.

Stakeholder Impact

• Shareholders: Potentially positive, as the director's interests are further aligned with long-term company performance and shareholder value creation.

Next Steps

• Cameron Turtle's continued service to Damora Therapeutics, Inc. to fulfill vesting conditions.

Key Dates

Keywords

Damora Therapeutics, DMRA, Cameron Turtle, Director, Stock Options, Insider Transaction, Equity Compensation, Vesting, Form 4